A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

by | Mar 18, 2026 | Clinical Trials | 0 comments

​ Conditions: Gastric (Stomach) Cancer; GastroEsophageal Cancer; Pancreatic Ductal Adenocarcinoma (mPDAC)

Interventions: Drug: DA-3501

Sponsors: Dong-A ST Co., Ltd.

Not yet recruiting Conditions: Gastric (Stomach) Cancer; GastroEsophageal Cancer; Pancreatic Ductal Adenocarcinoma (mPDAC)
Interventions: Drug: DA-3501
Sponsors: Dong-A ST Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *